Category: Members only
-
CVS Health makes headway in becoming environmentally sustainable
The progress and trend in the reduction of the GHG emissions and GHG emission intensity over the last six years reflect that CVS Health’s progress towards the goal of Net-zero by 2050 is on track.
-
ten23 health’s progress towards environmental sustainability
ten23 health has been voluntarily reporting its sustainability metrics. The company plans to become Net-zero by 2050.
-
Bayer’s efforts in environmental sustainability
The company aims to reduce its absolute Scope 1 and 2 GHG emissions by 42% by 2029, compared to 2019 base year levels.
-
Sanofi’s progress towards environmental sustainability
The French company has committed to achieving Net-zero emissions by 2045, with an intermediate carbon neutrality trajectory for 2030.
-
Novartis’ march towards achieving Net-zero by 2040
The company has committed to achieving Net-zero emissions by 2040 from the 2022 base year levels and maintaining it up to 2050.
-
Roche’s progress towards environmental sustainability
The Swiss company aims to have absolute zero emissions (for Scopes 1 and 2) by 2050 without the use of carbon credits or reduction claims.
-
AstraZeneca’s path to Net-zero
The company has reduced its Scope 1 and 2 GHG emissions by 77.5%, compared to 2015 base year levels, and is on track to reach the set target of 98% by 2026.
Latest posts
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.
-
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials
Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.